ClinicalTrials.gg

Program

SYH2072

A development code. Also written as “SYH2072 Tablets” and “SYH2072 tablets”.

Its studies are mostly in Hyperaldosteronism · Hypertension, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since Oct 28, 20263 company-led studies, 3 open or runningNext primary completion: Feb 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group33 open or runningphase 2since Oct 28, 2026May 8, 2026Feb 1, 2027phase 1 · NCT07647783

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 8, 2026First study: phase 1 study in Healthy ParticipantsFirst studyNCT07647783 · 112 planned · China
  2. Oct 28, 20262 phase 2 studiesPhase 2 reachedNCT07911735, NCT07917039

Ahead

  1. Feb 1, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07647783
  2. Jul 22, 2027Primary completion: phase 2 study in Uncontrolled HypertensionNCT07911735
  3. Feb 1, 2028Primary completion: phase 2 study in HyperaldosteronismNCT07917039

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07917039Hyperaldosteronism · China2Not yet recruitingFeb 1, 202860
NCT07911735Uncontrolled Hypertension2Not yet recruitingJul 22, 2027264
NCT07647783Healthy Participants · China1RecruitingFeb 1, 2027112

How it is read

Names in the registry

  • “SYH2072 Tablets”, 4 entries
  • “SYH2072 tablets”, 1 entry

Codes read as this program: SYH2072.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.